Core Viewpoint - Jyong Biotech Ltd. is experiencing fluctuations in its share price and increased trading volume following the expiry of the lock-up period, while engaging with investment funds interested in purchasing its shares [1]. Company Overview - Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with a target market in the U.S., EU, and Asia [6]. - The company has established integrated capabilities across all key functionalities of drug development since its inception in 2002, including drug discovery, clinical trials, and commercialization [6]. Financial and Operational Status - The company's research and development operations remain solid, and its financial condition is consistent with recent public filings, including the Current Report on Form 6-K [3]. - Jyong Biotech has completed four Phase III clinical trials in the U.S. and Taiwan, along with one Phase II clinical trial in Taiwan, and is advancing its investigational pipeline [5]. Strategic Developments - The company holds global multi-country invention patents, providing market protection across the Americas, Asia, and Europe, and has signed Letters of Intent (LOIs) with several international pharmaceutical companies [5]. - Jyong Biotech is committed to expanding its global presence and aims to deliver world-class botanical new drugs to address significant unmet medical needs [5]. Compliance and Disclosure - The company confirms compliance with SEC regulations and is not aware of any material, unpublished price-sensitive information that would explain the recent trading activity [2][4].

Core Insights - Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing innovative plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][3] - The chairwoman and CEO, Fu Feng Kuo, will speak at The 2025 Global Business Forum, discussing how Taiwan's biotech and medical industries can align with global trends [2][3] Company Overview - Jyong Biotech Ltd. was founded in 2002 and has developed integrated capabilities across all key drug development functions, including drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [3] - The company is advancing several botanical drug candidates, including its primary candidate BOTRESO and other clinical and preclinical candidates [3] Event Details - The Global Business Forum aims to facilitate direct dialogue between U.S. biotech decision-makers and Taiwan's leading drug development enterprises, focusing on strategic themes such as innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment [2][6]

Core Insights - Jyong Biotech Ltd. is a biotechnology company focused on developing plant-derived drugs for urinary system diseases, with a primary emphasis on the U.S., EU, and Asian markets [1][10] Group 1: Clinical Trials and Drug Development - The Phase III clinical trials for BOTRESO included two pivotal studies and two open-label extension studies, with results indicating significant improvement in lower urinary tract symptoms in the Asian subgroup compared to placebo [2] - BOTRESO is the first Taiwanese-developed oral botanical drug to receive IND approval from the U.S. FDA for Phase III trials, showcasing the company's innovative capabilities [4] - MCS-8 (PCP) demonstrated positive results in its Phase II trial, showing lower rates of positive prostate biopsies and high-grade prostate cancer compared to placebo, paving the way for further development [6] Group 2: Market Potential and Growth - The U.S. BPH patient population reached approximately 4.7 million in 2020, reflecting a 6.8% increase since 2017, while the global BPH patient count rose from 88.4 million in 2017 to 94.2 million in 2020 [5] - The global BPH drug market expanded from $3.7 billion in 2017 to $4.1 billion in 2020, with projections indicating it could reach $9.8 billion by 2026, highlighting significant growth potential [5] Group 3: Strategic Partnerships and Global Reach - Jyong Biotech maintains global patent coverage for BOTRESO and has signed multiple letters of intent and licensing agreements with international pharmaceutical partners to support global market entry [8] - The company is in discussions with global pharmaceutical partners for the further development of MCS-8, aiming to initiate large-scale Phase III trials involving thousands of participants [7]